Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Charcot-Marie-Tooth disease in which the cause of the disease is a mutation in the MORC2 gene.
Features include always present findings: Decreased motor nerve conduction velocity and Decreased amplitude of sensory action potentials; and common findings: Foot dorsiflexor weakness, Intrinsic hand muscle atrophy, Hyporeflexia, and Babinski sign and others. 36 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Gait ataxia, Ataxia, Fasciculations |
Muscles | 7 | Low muscle tone (hypotonia), Muscle spasm, Distal muscle weakness |
Arms and legs | 3 | Split hand, Foot dorsiflexor weakness, Intrinsic hand muscle atrophy |
Ears | 1 | Hearing loss (hearing impairment) |
Kidneys and urinary system | 1 | Urinary incontinence |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
MORC2 encodes MORC family CW-type zinc finger 2 (1,032 aa). ATP-dependent chromatin remodeler essential for epigenetic silencing by the HUSH (human silencing hub) complex. Highest expression in Testis (68.4 TPM) and Artery Tibial (33.4 TPM).
Charcot-Marie-Tooth disease axonal type 2Z is caused by mutations in the MORC2 gene on chromosome 22.
The MORC2 protein participates in ACLY tetramer transforms CIT to Ac-CoA pathway.
MORC2 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
Genetic testing for MORC2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 6 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease axonal type 2Z.
5 publications have been identified in PubMed for Charcot-Marie-Tooth disease axonal type 2Z. Research spans Basic Science / Preclinical (60%) and Case Report / Case Series (40%).
Wang M (2026). [PMID: 41548771](https://pubmed.ncbi.nlm.nih.gov/41548771/). *Pharmacol Res*. [Basic Science / Preclinical]
Kim JW (2025). [PMID: 40760337](https://pubmed.ncbi.nlm.nih.gov/40760337/). *Acta Neuropathol*. [Basic Science / Preclinical]
Chung HY (2024). [PMID: 38227798](https://pubmed.ncbi.nlm.nih.gov/38227798/). *Brain*. [Basic Science / Preclinical]
Hanada K (2024). [PMID: 39143067](https://pubmed.ncbi.nlm.nih.gov/39143067/). *Hum Genome Var*. [Case Report / Case Series]
Zhu F (2024). [PMID: 39464795](https://pubmed.ncbi.nlm.nih.gov/39464795/). *Front Genet*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 17, 2026, 7:31 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease axonal type 2Z